Core Insights - KORU Medical Systems, Inc. reported a quarterly loss of $0.02 per share, better than the Zacks Consensus Estimate of a loss of $0.03, marking an earnings surprise of +33.33% [1] - The company achieved revenues of $10.4 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 7.07% and showing a year-over-year increase from $8.18 million [2] - The stock has underperformed the market, losing approximately 3.1% year-to-date compared to the S&P 500's gain of 16.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $10.52 million, and for the current fiscal year, it is -$0.08 on revenues of $40.1 million [7] - The estimate revisions trend for KORU Medical Systems was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical Info Systems industry, to which KORU Medical Systems belongs, is currently ranked in the top 20% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Phreesia, is expected to report a quarterly loss of $0.01 per share, reflecting a year-over-year change of +96%, with revenues projected at $120.19 million, up 12.5% from the previous year [9][10]

Core Viewpoint - Phreesia reported quarterly earnings of $0.01 per share, exceeding the Zacks Consensus Estimate of a loss of $0.07 per share, marking a significant improvement from a loss of $0.31 per share a year ago, resulting in an earnings surprise of +114.29% [1] Financial Performance - The company achieved revenues of $117.26 million for the quarter ended July 2025, surpassing the Zacks Consensus Estimate by 0.70% and showing an increase from $102.11 million in the same quarter last year [2] - Over the last four quarters, Phreesia has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance - Phreesia shares have increased approximately 21% since the beginning of the year, outperforming the S&P 500's gain of 9.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $121.04 million, and for the current fiscal year, it is -$0.17 on revenues of $477.31 million [7] - The outlook for the Medical Info Systems industry, where Phreesia operates, is favorable, ranking in the top 34% of over 250 Zacks industries, suggesting potential for outperformance [8]

分组1 - Senseonics Holdings reported a quarterly loss of $0.02 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.03 per share a year ago [1] - The company posted revenues of $6.65 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4.46%, and up from $4.86 million year-over-year [2] - Senseonics has surpassed consensus revenue estimates three times over the last four quarters [2] 分组2 - The stock has underperformed, losing about 3.4% since the beginning of the year, while the S&P 500 gained 7.1% [3] - The company's earnings outlook and estimate revisions will be crucial for future stock performance [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $10.03 million, and -$0.07 on revenues of $36.46 million for the current fiscal year [7] 分组3 - The Medical Info Systems industry, to which Senseonics belongs, is currently in the top 30% of Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5]